English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Intrauterine adhesions (IUAs), also known as Asherman syndrome, was first reported by Asherman in 1894 (1). The prevalence ranges from 1.73% to 40%, and the symptoms include hypomenorrhea, amenorrhea, and periodic lower quadrant abdominal pain. IUAs affect pregnancy, having various presentations; for example, infertility, repeated pregnancy loss, poor implantation, and abnormal placentation (2-6). Surgery has been the standard treatment choice for the management of Asherman syndrome. Since surgical wounds are prone to re-adhesion, the postoperative recurrence rate is as high as 3.1–62.5% (2,7-8). In practice, surgeons have tried to use a series of solid and semi-solid barriers as secondary prevention strategies to supply an artificial interlayer between the uterine walls to prevent their fusion during the initial healing phase.

A novel intrauterine stent for prevention of intrauterine adhesions